187 related articles for article (PubMed ID: 15308519)
21. Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort.
McCarthy EM; Lee RZ; Ní Gabhann J; Smith S; Cunnane G; Doran MF; Howard D; O'Connell P; Kearns G; Jefferies CA
Rheumatology (Oxford); 2013 Jul; 52(7):1279-84. PubMed ID: 23479724
[TBL] [Abstract][Full Text] [Related]
22. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists.
Stohl W
Curr Dir Autoimmun; 2005; 8():289-304. PubMed ID: 15564726
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy.
Parodis I; Zickert A; Sundelin B; Axelsson M; Gerhardsson J; Svenungsson E; Malmström V; Gunnarsson I
Lupus Sci Med; 2015; 2(1):e000061. PubMed ID: 25632350
[TBL] [Abstract][Full Text] [Related]
24. Targeting the BLyS-APRIL signaling pathway in SLE.
La Cava A
Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
[TBL] [Abstract][Full Text] [Related]
25. 17-β-estradiol affects BLyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB/WF1 mice.
Bassi N; Luisetto R; Ghirardello A; Gatto M; Valente M; Della Barbera M; Nalotto L; Punzi L; Doria A
Lupus; 2015 Apr; 24(4-5):382-91. PubMed ID: 25801881
[TBL] [Abstract][Full Text] [Related]
26. [B lymphocyte stimulator (BLyS/BAFF) level in sera of patients with lupus].
Mercado U; Díaz-Molina R
Rev Med Inst Mex Seguro Soc; 2016; 54(3):334-7. PubMed ID: 27100979
[TBL] [Abstract][Full Text] [Related]
27. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus.
Carter RH; Zhao H; Liu X; Pelletier M; Chatham W; Kimberly R; Zhou T
Arthritis Rheum; 2005 Dec; 52(12):3943-54. PubMed ID: 16320342
[TBL] [Abstract][Full Text] [Related]
28. SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder.
Stohl W
Arthritis Res Ther; 2003; 5(3):136-8. PubMed ID: 12723979
[TBL] [Abstract][Full Text] [Related]
29. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
[TBL] [Abstract][Full Text] [Related]
30. Serum amyloid P component-DNA complexes are decreased in systemic lupus erythematosus. inverse association with anti-dsDNA antibodies.
Voss A; Nielsen EH; Svehag SE; Junker P
J Rheumatol; 2008 Apr; 35(4):625-30. PubMed ID: 18278838
[TBL] [Abstract][Full Text] [Related]
31. The effect of BLyS on the activity of peripheral B lymphocytes mediated by BLyS receptors in patients with systemic lupus erythematosus.
Cheng Y; Yan S; Zhao W; Huang Q; Lian L; Wei W
Scand J Clin Lab Invest; 2013 Mar; 73(2):141-7. PubMed ID: 23336587
[TBL] [Abstract][Full Text] [Related]
32. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis.
Kawasaki A; Tsuchiya N; Fukazawa T; Hashimoto H; Tokunaga K
Genes Immun; 2002 Nov; 3(7):424-9. PubMed ID: 12424625
[TBL] [Abstract][Full Text] [Related]
33. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q.
Mok CC; Birmingham DJ; Ho LY; Hebert LA; Song H; Rovin BH
Lupus; 2012 Jan; 21(1):36-42. PubMed ID: 21993384
[TBL] [Abstract][Full Text] [Related]
34. Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus.
Jolly M; Francis S; Aggarwal R; Mikolaitis RA; Niewold TB; Chubinskaya S; Block JA; Scanzello C; Sequeira W
Lupus; 2014 Aug; 23(9):881-8. PubMed ID: 24786785
[TBL] [Abstract][Full Text] [Related]
35. Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein.
Stohl W
Curr Opin Rheumatol; 2002 Sep; 14(5):522-8. PubMed ID: 12192248
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and clinico-serological correlations of anti-alpha-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus.
Mosca M; Chimenti D; Pratesi F; Baldini C; Anzilotti C; Bombardieri S; Migliorini P
J Rheumatol; 2006 Apr; 33(4):695-7. PubMed ID: 16583471
[TBL] [Abstract][Full Text] [Related]
37. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome.
Gottenberg JE; Busson M; Cohen-Solal J; Lavie F; Abbed K; Kimberly RP; Sibilia J; Mariette X
Ann Rheum Dis; 2005 Jul; 64(7):1050-5. PubMed ID: 15640273
[TBL] [Abstract][Full Text] [Related]
38. Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus.
Mok CC; Ho LY; Leung HW; Wong LG
Transl Res; 2010 Dec; 156(6):320-5. PubMed ID: 21078493
[TBL] [Abstract][Full Text] [Related]
39. Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.
Gordon C; Wofsy D; Wax S; Li Y; Pena Rossi C; Isenberg D
Arthritis Rheumatol; 2017 Jan; 69(1):122-130. PubMed ID: 27390168
[TBL] [Abstract][Full Text] [Related]
40. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
